Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9Y448

UPID:
SKAP_HUMAN

ALTERNATIVE NAMES:
Kinetochore-localized astrin-binding protein; Kinetochore-localized astrin/SPAG5-binding protein; TRAF4-associated factor 1

ALTERNATIVE UPACC:
Q9Y448; B4DXA7; Q147U5; Q32Q57; Q5ISJ0; Q6P2S5; Q6PJM0; Q86XB4

BACKGROUND:
The Small kinetochore-associated protein, essential for faithful chromosome segregation and cell division, interacts with components like astrin and kinastrin to promote stable microtubule-kinetochore attachments. Its role extends to ensuring the normal timing of sister chromatid segregation and maintaining spindle pole architecture, which are crucial for the integrity of cell division.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Small kinetochore-associated protein could open doors to potential therapeutic strategies, especially considering its involvement in Roifman-Chitayat syndrome. This insight offers a promising avenue for addressing complex diseases linked to cell division anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.